Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia.

Cillóniz C, Dominedò C, Ielpo A, Ferrer M, Gabarrús A, Battaglini D, Bermejo-Martin J, Meli A, García-Vidal C, Liapikou A, Singer M, Torres A.

J Clin Med. 2019 Jul 2;8(7). pii: E961. doi: 10.3390/jcm8070961.

2.

Emerging strategies for the noninvasive diagnosis of nosocomial pneumonia.

Liapikou A, Cillóniz C, Torres A.

Expert Rev Anti Infect Ther. 2019 Jul;17(7):523-533. doi: 10.1080/14787210.2019.1635010. Epub 2019 Jun 25.

PMID:
31237462
3.

Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia.

Ceccato A, Panagiotarakou M, Ranzani OT, Martin-Fernandez M, Almansa-Mora R, Gabarrus A, Bueno L, Cilloniz C, Liapikou A, Ferrer M, Bermejo-Martin JF, Torres A.

J Clin Med. 2019 Jun 13;8(6). pii: E843. doi: 10.3390/jcm8060843.

4.

Drugs that increase the risk of community-acquired pneumonia: a narrative review.

Liapikou A, Cilloniz C, Torres A.

Expert Opin Drug Saf. 2018 Oct;17(10):991-1003. doi: 10.1080/14740338.2018.1519545. Epub 2018 Sep 17. Review.

PMID:
30196729
5.

Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia.

Cillóniz C, Liapikou A, Martin-Loeches I, García-Vidal C, Gabarrús A, Ceccato A, Magdaleno D, Mensa J, Marco F, Torres A.

PLoS One. 2018 Jul 18;13(7):e0200504. doi: 10.1371/journal.pone.0200504. eCollection 2018.

6.

Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia.

Cilloniz C, Ferrer M, Liapikou A, Garcia-Vidal C, Gabarrus A, Ceccato A, Puig de La Bellacasa J, Blasi F, Torres A.

Eur Respir J. 2018 Mar 29;51(3). pii: 1702215. doi: 10.1183/13993003.02215-2017. Print 2018 Mar.

PMID:
29545274
7.

Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients.

Ferrer M, Travierso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino E, Liapikou A, Blasi F, Torres A.

PLoS One. 2018 Jan 25;13(1):e0191721. doi: 10.1371/journal.pone.0191721. eCollection 2018.

8.

Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia.

Liapikou A, Cillóniz C, Torres A.

Expert Opin Investig Drugs. 2017 Nov;26(11):1239-1248. doi: 10.1080/13543784.2017.1385761. Epub 2017 Oct 3. Review.

PMID:
28952384
9.

Emerging drugs for nosocomial pneumonia.

Liapikou A, Torres A.

Expert Opin Emerg Drugs. 2016 Sep;21(3):331-41. doi: 10.1080/14728214.2016.1206077. Epub 2016 Jul 7. Review.

PMID:
27347712
10.

Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.

Liapikou A, Dimakou K, Toumbis M.

Ther Adv Respir Dis. 2016 Aug;10(4):368-78. doi: 10.1177/1753465816651594. Epub 2016 Jun 23. Review.

11.

Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia.

Amaro R, Liapikou A, Cilloniz C, Gabarrus A, Marco F, Sellares J, Polverino E, Garau J, Ferrer M, Musher DM, Torres A.

Eur Respir J. 2016 Sep;48(3):797-807. doi: 10.1183/13993003.00039-2016. Epub 2016 May 12.

12.

Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia.

Liapikou A, Cillóniz C, Gabarrús A, Amaro R, De la Bellacasa JP, Mensa J, Sánchez M, Niederman M, Torres A.

Eur Respir J. 2016 Jul;48(1):257-61. doi: 10.1183/13993003.00191-2016. Epub 2016 Apr 21. No abstract available.

13.

Readmission for Acute Exacerbation within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase in Mortality Risk in COPD Patients: A Long-Term Observational Study.

Guerrero M, Crisafulli E, Liapikou A, Huerta A, Gabarrús A, Chetta A, Soler N, Torres A.

PLoS One. 2016 Mar 4;11(3):e0150737. doi: 10.1371/journal.pone.0150737. eCollection 2016.

14.

The clinical management of lower respiratory tract infections.

Liapikou A, Torres A.

Expert Rev Respir Med. 2016 Apr;10(4):441-452. doi: 10.1586/17476348.2016.1156537. Epub 2016 Mar 16.

PMID:
26894943
15.

Polymicrobial intensive care unit-acquired pneumonia: prevalence, microbiology and outcome.

Ferrer M, Difrancesco LF, Liapikou A, Rinaudo M, Carbonara M, Li Bassi G, Gabarrus A, Torres A.

Crit Care. 2015 Dec 23;19:450. doi: 10.1186/s13054-015-1165-5.

16.

Ceftobiprole for the treatment of pneumonia: a European perspective.

Liapikou A, Cillóniz C, Torres A.

Drug Des Devel Ther. 2015 Aug 18;9:4565-72. doi: 10.2147/DDDT.S56616. eCollection 2015. Review.

17.

Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia.

Liapikou A, Toumbis M, Torres A.

Expert Opin Drug Saf. 2015 Aug;14(8):1237-47. doi: 10.1517/14740338.2015.1057494. Epub 2015 Jun 25. Review.

PMID:
26113207
18.

The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia.

Cilloniz C, Albert RK, Liapikou A, Gabarrus A, Rangel E, Bello S, Marco F, Mensa J, Torres A.

Am J Respir Crit Care Med. 2015 Jun 1;191(11):1265-72. doi: 10.1164/rccm.201502-0212OC.

PMID:
25807239
19.

C-Reactive Protein at Discharge, Diabetes Mellitus and ≥ 1 Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Crisafulli E, Torres A, Huerta A, Méndez R, Guerrero M, Martinez R, Liapikou A, Soler N, Sethi S, Menéndez R.

COPD. 2015 Jun;12(3):306-14. doi: 10.3109/15412555.2014.933954. Epub 2014 Oct 3.

PMID:
25279441
20.

Pharmacotherapy for lower respiratory tract infections.

Liapikou A, Torres A.

Expert Opin Pharmacother. 2014 Nov;15(16):2307-18. doi: 10.1517/14656566.2014.959927. Epub 2014 Sep 12. Review. Erratum in: Expert Opin Pharmacother. 2014 Dec;15(18):2755. Adamantia, Liapikou [corrected to Liapikou, Adamantia]; Torres, Antonio [corrected to Torres, Antoni].

PMID:
25216725
21.

New antimicrobial approaches to gram positive respiratory infections.

Liapikou A, Cilloniz C, Mensa J, Torres A.

Pulm Pharmacol Ther. 2015 Jun;32:137-43. doi: 10.1016/j.pupt.2014.05.003. Epub 2014 May 27. Review.

PMID:
24878422
22.

The management of severe community acquired pneumonia in the intensive care unit.

Liapikou A, Rosales-Mayor E, Torres A.

Expert Rev Respir Med. 2014 Jun;8(3):293-303. doi: 10.1586/17476348.2014.896202. Review.

PMID:
24838089
23.

Pharmacotherapy for hospital-acquired pneumonia.

Liapikou A, Rosales-Mayor E, Torres A.

Expert Opin Pharmacother. 2014 Apr;15(6):775-86. doi: 10.1517/14656566.2014.889115. Epub 2014 Feb 28. Review.

PMID:
24579912
24.

A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia.

Liapikou A, Polverino E, Cilloniz C, Peyrani P, Ramirez J, Menendez R, Torres A; Community-Acquired Pneumonia Organization (CAPO) Investigators.

Respir Care. 2014 Jul;59(7):1078-85. doi: 10.4187/respcare.02788. Epub 2013 Nov 5.

25.

Emerging drugs on methicillin-resistant Staphylococcus aureus.

Liapikou A, Torres A.

Expert Opin Emerg Drugs. 2013 Sep;18(3):291-305. doi: 10.1517/14728214.2013.813480. Epub 2013 Jul 13. Review.

PMID:
23848400
26.

Current treatment of community-acquired pneumonia.

Liapikou A, Torres A.

Expert Opin Pharmacother. 2013 Jul;14(10):1319-32. doi: 10.1517/14656566.2013.798647. Epub 2013 May 10. Review.

PMID:
23663104
27.

What is the best approach to the nonresponding patient with community-acquired pneumonia?

Sialer S, Liapikou A, Torres A.

Infect Dis Clin North Am. 2013 Mar;27(1):189-203. doi: 10.1016/j.idc.2012.11.009. Review.

PMID:
23398874
28.

Levofloxacin for the treatment of respiratory tract infections.

Torres A, Liapikou A.

Expert Opin Pharmacother. 2012 Jun;13(8):1203-12. doi: 10.1517/14656566.2012.688952. Review.

PMID:
22594848
29.

Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients.

Liapikou A, Polverino E, Ewig S, Cillóniz C, Marcos MA, Mensa J, Bello S, Martin-Loeches I, Menéndez R, Torres A.

Eur Respir J. 2012 Apr;39(4):855-61. doi: 10.1183/09031936.00067111. Epub 2011 Sep 15.

30.

Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients.

Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo LM, Zavala E, Welte T, Torres A.

Am J Respir Crit Care Med. 2010 Dec 15;182(12):1533-9. doi: 10.1164/rccm.201001-0094OC. Epub 2010 Aug 6.

PMID:
20693381
31.

Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit.

Ferrer M, Liapikou A, Valencia M, Esperatti M, Theessen A, Antonio Martinez J, Mensa J, Torres A.

Clin Infect Dis. 2010 Apr 1;50(7):945-52. doi: 10.1086/651075.

PMID:
20175690
32.

Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission.

Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piñer R, Mensa J, Luque N, Ewig S, Menendez R, Niederman MS, Torres A.

Clin Infect Dis. 2009 Feb 15;48(4):377-85. doi: 10.1086/596307.

PMID:
19140759
33.

Exclusive diagnostic contribution of the histology specimens obtained by 19-gauge transbronchial aspiration needle in suspected malignant intrathoracic lymphadenopathy.

Stratakos G, Porfyridis I, Papas V, Kandaraki C, Zisis C, Mariatou V, Liapikou A, Roussos C, Zakynthinos S.

Chest. 2008 Jan;133(1):131-6. Epub 2007 Oct 20.

PMID:
17951614
34.

Tracheoesophageal fistula managed with tracheal stent through flexible bronchoscopy without fluoroscopy.

Stratakos G, Zisis C, Bellenis I, Filaditaki V, Liapikou A, Zakynthinos S, Roussos C.

Monaldi Arch Chest Dis. 2006 Dec;65(4):225-7.

PMID:
17393669
35.

Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire.

Gaga M, Papageorgiou N, Yiourgioti G, Karydi P, Liapikou A, Bitsakou H, Zervas E, Koulouris NG, Holgate ST; ENFUMOSA Study Group.

Clin Exp Allergy. 2005 Jul;35(7):954-9.

PMID:
16008684

Supplemental Content

Loading ...
Support Center